Phoenix PharmaLabs’ technology is based on the discovery of a family of ligands with high binding affinity at all three opiate receptors: mu, kappa, and delta. These unique ligands, derived from opioid backbones using PPL’s proprietary technology, manifest balanced partial agonism/antagonism of all three opiate receptors. They are the first ever opioid analgesics showing no significant signs of euphoria (which leads to abuse and addiction) as well as no dysphoria, constipation, or other dangerous opiate side-effects in extensive animal studies.
The Company’s Current I.P. Estate